The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Key factors in the rising cost of new drug discovery and development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
National Conference of State Legislatures
(2011) · Reference Reviews · doi:10.1108/09504121111114072 · Cited by 2,315
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
Returns on Research and Development for 1990s New Drug Introductions
Grabowski, H., Vernon, J., & DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00002 · Cited by 311
A New Look at the Returns and Risks to Pharmaceutical R&D
Grabowski, H., & Vernon, J. (1990) · Management Science · doi:10.1287/mnsc.36.7.804 · Cited by 286
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00001 · Cited by 233
Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS
Lichtenberg, F. R. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.241 · Cited by 214
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Hybrid Molecules with a Dual Mode of Action: Dream or Reality?
Meunier, B. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000843 · Cited by 929
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
The pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Sung, J. H., Kam, C., & Shuler, M. L. (2010) · Lab on a Chip · doi:10.1039/b917763a · Cited by 484
Metadata
- Authors
- Dickson, M., & Gagnon, J. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-05
- Volume
- 3
- Issue
- 5
- Pages
- 417-429
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2044424923
- Cited by
- 498
- References
- 25
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Key factors in the rising cost of new drug discovery and development. https://app.cochat.ai/papers/10.1038/nrd1382
- The paper
- Dickson, M., & Gagnon, J. P. (2004). Key factors in the rising cost of new drug discovery and development. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.